VBIO · XBRL financial data

Valion Bio financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (VBIO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Revenue	282	357*	334	140	126	180*	70	86	—	—	—	—
Revenue from contracts with customers	—	—	—	—	126	—	—	—	146	—	—	—
Cost of revenue	174	352*	167	110	82	419*	20	32	—	—	—	—
Cost of goods and services sold	—	—	—	—	82	—	—	—	291	—	—	—
Gross profit	108	5*	167	30	44	(239)*	50	54	(145)	—	—	—
Research and development	337	360*	256	302	422	333*	335	655	858	1,283*	1,854	2,704
Selling, general and administrative	—	—	—	—	—	year only	1,042	1,023	—	year only	3,780	3,720
General and administrative	1,051	1,154*	887	727	819	730*	1,042	907	1,065	—	—	—
Total operating expenses	1,868	2,249*	1,648	1,236	1,475	1,304*	1,556	1,988	2,338	2,016*	5,634	6,424
Operating income (loss)	(1,760)	(2,244)*	(1,481)	(1,206)	(1,431)	(1,543)*	(1,506)	(1,934)	(2,483)	(1,975)*	(5,634)	(6,424)
Interest income	—	—	—	—	0	6*	4	3	4	12*	24	11
Interest expense	—	—	—	—	—	year only	0	0	—	year only	648	691
Income tax expense (benefit)	—	—	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	(1,760)	(2,243)*	(1,481)	(1,266)	(1,431)	(1,477)*	(1,502)	(1,931)	(2,596)	(2,849)*	(6,202)	(7,103)
Earnings per share, basic‡ USD per share	(25.17)	—	(17.18)	(5.44)	(3.91)	—	(2.52)	(2.19)	(1.97)	—	(2.23)	(2.17)
Earnings per share, diluted‡ USD per share	(25.17)	—	(17.18)	(5.44)	(3.91)	—	(2.52)	(2.19)	—	—	—	—
Weighted average shares, basic‡ thousands of shares	70	—	86	236	364	—	596	881	1,321	—	2,884	3,380
Weighted average shares, diluted‡ thousands of shares	70	—	86	236	364	—	596	881	—	—	—	—

‡ Per-share figures and share counts are adjusted for the 1-for-17.006802721088437 stock split (March 2025); filings made before it reported them unadjusted.
† Share count changed about 1/13 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 24x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 7x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (VBIO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Cash and cash equivalents	5,169	3,395	1,668	3,693	2,189	2,002	669	1,184	3,450	12,645	7,215	2,108
Accounts receivable	131	174	74	16	9	69	13	13	19	—	—	—
Inventory	928	756	774	766	731	319	306	283	4	0	750	750
Prepaid and other current assets	227	327	250	188	234	249	273	362	267	346	687	524
Total current assets	6,455	4,652	2,827	4,663	3,163	2,639	1,261	1,842	3,740	13,006	8,652	3,382
Property and equipment, net	124	122	121	120	119	119	118	120	12	12,641	12,644	12,343
Right-of-use asset	394	349	304	—	—	—	—	—	—	0	10,086	9,835
Goodwill	—	—	—	—	—	0	—	—	—	3,457	3,457	3,457
Total assets	7,007	5,157	3,286	4,783	3,394	2,807	3,777	4,508	6,229	31,607	38,215	32,473
Accounts payable	638	713	547	446	333	125	438	234	465	264	629	639
Total current liabilities	1,000	1,401	992	591	560	272	741	821	638	646	2,615	3,046
Lease liability, non-current	242	176	141	0	0	—	—	—	—	0	9,643	9,488
Total liabilities	1,242	1,577	1,133	591	560	272	741	821	638	7,440	19,667	20,588
Accumulated deficit	(35,643)	(37,886)	(39,367)	(40,633)	(42,064)	(43,541)	(45,043)	(46,975)	(49,617)	(52,597)	(59,034)	(66,506)
Total stockholders' equity	5,765	3,580	2,153	4,192	2,834	2,535	3,036	3,687	5,591	16,797	11,062	4,246
Total liabilities and equity	7,007	5,157	3,286	4,783	3,394	2,807	3,777	4,508	6,229	31,607	38,215	32,473
Common shares outstanding (cover page)‡ thousands of shares	86	86	364	364	486	36	878	1,083	1,766	2,878	3,201	22,190

‡ Per-share figures and share counts are adjusted for the 1-for-17.006802721088437 stock split (March 2025); filings made before it reported them unadjusted.
† Share count changed about 1/13 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 24x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 7x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (VBIO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26†Jun 30, 2026
Net income (loss)	(1,760)	(2,243)*	(1,481)	(1,266)	(1,431)	(1,477)*	(1,502)	(1,931)	(2,596)	(2,849)*	(6,202)	(7,103)
Stock-based compensation	48*	58*	54	54*	58*	63*	100	176*	139*	149*	208	133*
Depreciation and amortization	1	2*	1	1	1	0*	1	1	—	—	—	—
Net cash from operating activities	(1,871)*	(1,774)*	(1,666)	(1,287)*	(1,407)*	(1,365)*	(889)	(1,827)*	(1,996)*	(2,287)*	(5,011)	(5,281)*
Purchases of property and equipment	0*	0*	—	—	—	0*	0	3*	10*	25*	7	57*
Net cash from investing activities	0*	0*	—	—	—	0*	(526)	(20)*	(10)*	(149)*	(7)	(57)*
Proceeds from issuing common stock	4,316*	0*	—	—	(3,251)*	4,381*	—	—	429*	0*	—	—
Net cash from financing activities	4,381*	0*	(61)	3,312*	(97)*	1,178*	82	2,362*	4,272*	11,631*	(44)	231*
Net change in cash	2,510*	(1,774)*	(1,727)	2,025*	(1,504)*	(187)*	(1,333)	515*	2,266*	9,195*	(5,062)	(5,107)*

† Share count changed about 1/13 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 24x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 7x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Valion Bio	2,108	not reported	(5,281)*	22.2M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Healthy Extracts	190	2,067	306*	14.7M	—	Q2 FY26 10-QJun 30, 2026
Theriva Biologics	11,337	0*	(3,085)*	45.9M	3.7 quarters	Q2 FY26 10-QJun 30, 2026
Jaguar Health	3,788	1,225	(5,338)*	not reported	0.7 quarters	Q2 FY26 10-QJun 30, 2026
China Pharma Holdings	305	948	(33)*	43.0M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Synlogic	13,183	0	(922)*	12.2M	14.3 quarters	Q2 FY26 10-QJun 30, 2026
Q/C Technologies	308	not reported	(1,819)*	8.2M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
Polomar Health Services	179	1,529	121*	28.4M	—	Q2 FY26 10-QJun 30, 2026
Enveric Biosciences	8,296	not reported	(2,445)*	4.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.